These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

773 related articles for article (PubMed ID: 16611537)

  • 21. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
    Lazarus HM; Loberiza FR; Zhang MJ; Armitage JO; Ballen KK; Bashey A; Bolwell BJ; Burns LJ; Freytes CO; Gale RP; Gibson J; Herzig RH; LeMaistre CF; Marks D; Mason J; Miller AM; Milone GA; Pavlovsky S; Reece DE; Rizzo JD; van Besien K; Vose JM; Horowitz MM
    Bone Marrow Transplant; 2001 Feb; 27(4):387-96. PubMed ID: 11313668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
    Kebriaei P; Kline J; Stock W; Kasza K; Le Beau MM; Larson RA; van Besien K
    Bone Marrow Transplant; 2005 May; 35(10):965-70. PubMed ID: 15806131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation.
    Bug G; Atta J; Klein SA; Hertenstein B; Bergmann L; Boehrer S; Mousset S; Hoelzer D; Martin H
    Ann Hematol; 2005 Oct; 84(11):748-54. PubMed ID: 16001243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome.
    Fung HC; Stein A; Slovak Ml; O'donnell MR; Snyder DS; Cohen S; Smith D; Krishnan A; Spielberger R; Bhatia R; Bhatia S; Falk P; Molina A; Nademanee A; Parker P; Rodriguez R; Rosenthal J; Sweetman R; Kogut N; Sahebi F; Popplewell L; Vora N; Somlo G; Margolin K; Chow W; Smith E; Forman SJ
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):766-71. PubMed ID: 14677116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autologous bone marrow transplantation for acute myeloid leukemia in remission or first relapse using monoclonal antibody-purged marrow: results of phase II studies with long-term follow-up.
    Ball ED; Wilson J; Phelps V; Neudorf S
    Bone Marrow Transplant; 2000 Apr; 25(8):823-9. PubMed ID: 10808202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.
    Tauro S; Craddock C; Peggs K; Begum G; Mahendra P; Cook G; Marsh J; Milligan D; Goldstone A; Hunter A; Khwaja A; Chopra R; Littlewood T; Peniket A; Parker A; Jackson G; Hale G; Cook M; Russell N; Mackinnon S
    J Clin Oncol; 2005 Dec; 23(36):9387-93. PubMed ID: 16314618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Bone marrow autotransplantation in acute myeloblastic leukemia in its first complete remission. The clinical results in 41 patients].
    Tomás JF; Gómez-García de Soria V; Pinilla I; Lamana M; Figuera A; Arranz R; Cámara R; Fernández-Villalta MJ; Alegre A; Fernández-Rañada JM
    Med Clin (Barc); 1997 Feb; 108(6):201-6. PubMed ID: 9102484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or =60 years with acute myelogenous leukemia.
    Lashkari A; Lowe T; Collisson E; Paquette R; Emmanouilides C; Territo M; Schiller G
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):466-71. PubMed ID: 16545730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
    Jerjis S; Roovers E; Muus P; Schaap N; de Witte T
    Bone Marrow Transplant; 1998 Jul; 22(1):13-9. PubMed ID: 9678790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
    Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
    Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy.
    Brunet S; Esteve J; Berlanga J; Ribera JM; Bueno J; Martí JM; Bargay J; Guardia R; Juliá A; Granena A; Montserrat E; Sierra J;
    Haematologica; 2004 Aug; 89(8):940-9. PubMed ID: 15339677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response.
    Ganguly S; Divine CL; Deauna-Limayo D; Bodensteiner DC; Cook JD; Lewis JN; Skikne BS
    Ann Hematol; 2005 Aug; 84(8):526-31. PubMed ID: 15915350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autologous stem cell transplantation using modified TAM or combination of triple-alkylating agents conditioning regimens as one of the post-remission treatments in patients with adult acute myeloid leukemia in first complete remission.
    Kim HJ; Min WS; Eom KS; Park SJ; Park YH; Kim DW; Lee JW; Park CW; Kim CC
    Bone Marrow Transplant; 2004 Aug; 34(3):215-20. PubMed ID: 15170169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 Trial.
    Ribera JM; Ortega JJ; Oriol A; Bastida P; Calvo C; Pérez-Hurtado JM; González-Valentín ME; Martín-Reina V; Molinés A; Ortega-Rivas F; Moreno MJ; Rivas C; Egurbide I; Heras I; Poderós C; Martínez-Revuelta E; Guinea JM; del Potro E; Deben G
    J Clin Oncol; 2007 Jan; 25(1):16-24. PubMed ID: 17194902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
    J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
    Visani G; Lemoli RM; Isidori A; Piccaluga PP; Martinelli G; Malagola M; Gugliotta L; Bonini A; Bonifazi F; Motta MR; Rizzi S; Castellani S; Tura S
    Bone Marrow Transplant; 2001 Apr; 27(8):829-35. PubMed ID: 11477440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia.
    Anagnostopoulos A; Hari PN; Pérez WS; Ballen K; Bashey A; Bredeson CN; Freytes CO; Gale RP; Gertz MA; Gibson J; Goldschmidt H; Lazarus HM; McCarthy PL; Reece DE; Vesole DH; Giralt SA
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):845-54. PubMed ID: 16864055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of conditioning regimen in allogeneic hematopoetic stem cell transplantation for children with acute myelogenous leukemia beyond first complete remission: a pediatric blood and marrow transplant consortium (PBMTC) study.
    Sisler IY; Koehler E; Koyama T; Domm JA; Ryan R; Levine JE; Pulsipher MA; Haut PR; Schultz KR; Taylor DS; Frangoul HA
    Biol Blood Marrow Transplant; 2009 Dec; 15(12):1620-7. PubMed ID: 19896086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autologous stem cell transplantation for elderly patients with acute myeloid leukaemia conditioned with continuous infusion idarubicin and busulphan.
    Ferrara F; Palmieri S; Pedata M; Viola A; Izzo T; Criscuolo C; Mele G
    Hematol Oncol; 2009 Mar; 27(1):40-5. PubMed ID: 19206083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.